Don't Miss the Sept. 20 CERSI Lecture Series: Antibody-Targeted Cancer Immunotherapy, Georgetown University CERSI

Don't miss the first lecture in FDA's new CERSI lecture series

The lecture series presents current research and advancements in regulatory science related to pre-clinical evaluation of safety and efficacy of medical products, emerging technologies, and assessing diverse data sets through information sciences to improve health outcomes. Lectures are presented by scientists from the CERSI academic institutions or collaborators of CERSI investigators.

Antibody-Targeted Cancer Immunotherapy, Georgetown University CERSI

Tuesday, September 20, 2016
11:00 a.m. to 12:00 p.m., Eastern Daylight Time (EDT)

Presented by

Louis M. Weiner, MD
Director, Georgetown Lombardi Comprehensive Cancer Center
Professor and Chair, Department of Oncology 
Georgetown University School of Medicine

About the Presentation

Antibodies have become a part of the standard cancer therapy armamentarium. These versatile platforms can be used to deliver toxic payloads or to manipulate cancer cell signaling. Exciting clinical results with immune checkpoint inhibitors demonstrate that antibodies can powerfully modulate the anti-cancer immune response. Our work focuses on using antibodies to manipulate hot immunity and to understand mechanisms of tumor resistance that can be attacked to promote effective antibody-targeted cancer immunotherapy.

For further information and for remote access, visit FDA's Website.